Ranibizumab Combined With Verteporfin Photodynamic Therapy in Neovascular Age-related Macular Degeneration (FOCUS): Year 2 Results
- 13 February 2008
- journal article
- research article
- Published by Elsevier
- Vol. 145 (5) , 862-874.e3
- https://doi.org/10.1016/j.ajo.2007.12.029
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Ranibizumab Combined With Verteporfin Photodynamic Therapy in Neovascular Age-Related Macular DegenerationArchives of Ophthalmology (1950), 2006
- Ranibizumab versus Verteporfin for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006
- Ranibizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006
- Tolerability and Efficacy of Multiple Escalating Doses of Ranibizumab (Lucentis) for Neovascular Age-Related Macular DegenerationOphthalmology, 2006
- Ranibizumab for Treatment of Neovascular Age-Related Macular DegenerationOphthalmology, 2006
- Maximum Tolerated Dose of a Humanized Anti–Vascular Endothelial Growth Factor Antibody Fragment for Treating Neovascular Age-Related Macular DegenerationOphthalmology, 2005
- VERTEPORFIN THERAPY OF SUBFOVEAL CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATIONRetina, 2004
- Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization—verteporfin in photodynamic therapy report 2American Journal of Ophthalmology, 2001
- Photodynamic Therapy of Subfoveal Choroidal Neovascularization in Age-related Macular Degeneration With VerteporfinArchives of Ophthalmology (1950), 1999
- Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patientsBMJ, 1994